BIOMAT Database Logo BIOMAT Database Logo

Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group. 1990

K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
Fujita Health University School of Medicine, Toyoake.

A cooperative randomized clinical trial to compare the effectiveness of multi-drug combination chemotherapy (VMCP), vincristine-melphalan-cyclophosphamide-prednisolone) with CP (cyclophosphamide-prednisolone) for the treatment of multiple myeloma was performed. When the whole group of patients was evaluated, the choice of chemotherapy (VMCP or CP) was not a significant prognostic factor associated with response or survival by uni- or multivariate analysis, and the difference between the survival curves of the treatment groups was only marginally significant. However, when the analysis was confined to stage III patients, the choice of chemotherapy became a significant prognostic factor associated with both response rate and survival, and the statistical difference between survival curves was significant. Taking the disease characteristics of multiple myeloma into consideration, the better result obtained with multi-drug combination chemotherapy in the treatment of stage III patients is consistent with other studies supporting the superiority of multi-drug combination chemotherapy for patients with overt systemic disease.

UI MeSH Term Description Entries
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG).
August 1993, European journal of haematology,
K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
[Combination chemotherapy with melphalan, cyclophosphamide, vincristine, ACNU and prednisolone (MEV(Ac)P) for multiple myeloma].
December 1986, [Rinsho ketsueki] The Japanese journal of clinical hematology,
K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
[Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
May 1984, Revue du rhumatisme et des maladies osteo-articulaires,
K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
January 2012, Mymensingh medical journal : MMJ,
K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
Combination chemotherapy for multiple myeloma with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine.
June 1988, Acta medica Okayama,
K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
January 1981, Archivum immunologiae et therapiae experimentalis,
K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
April 1997, Cancer,
K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group.
February 1994, International journal of hematology,
K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
February 2004, International journal of hematology,
K Shimizu, and O Kamiya, and N Hamajima, and H Mizuno, and M Kobayashi, and N Hirabayashi, and H Takeyama, and R Kato, and K Kawashima, and M Nitta
Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
April 2011, Japanese journal of clinical oncology,
Copied contents to your clipboard!